A global treatments for coronaviruses including COVID-19.
Reads0
Chats0
TLDR
A therapeutic window of drugs available to patients with coronavirus disease‐19 is reached and an ACE2 inhibitor and a clinical problem reducing agent such as favipiravir in addition to hydroxychloroquine and corticosteroids are reached.Citations
More filters
Journal ArticleDOI
A bibliometric analysis using VOSviewer of publications on COVID-19
Yuetian Yu,Yujie Li,Zhongheng Zhang,Zhi-Chun Gu,Han Zhong,Qiongfang Zha,Luyu Yang,Cheng Zhu,Erzhen Chen +8 more
TL;DR: The current growth trends predict a large increase in the number of global publications on COVID-19, and China made the most outstanding contribution within this important field.
Journal ArticleDOI
Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications.
Ioannis P. Trougakos,Kimon Stamatelopoulos,Evangelos Terpos,Ourania E. Tsitsilonis,Evmorfia Aivalioti,Dimitrios Paraskevis,Efstathios Kastritis,George N. Pavlakis,Meletios-Athanasios Dimopoulos +8 more
TL;DR: In this paper, the authors discuss SARS-CoV-2 life cycle and a number of approaches aiming to suppress viral infection rates or propagation; increase virus antigen presentation in order to activate a robust and durable adaptive immune response from the host, and/or mitigate the ARDS-related "cytokine storm" and collateral tissue damage that triggers the severe life-threatening complications of COVID-19.
Journal ArticleDOI
Cathepsin L in COVID-19: From Pharmacological Evidences to Genetics.
Caio Perez Gomes,Danilo Euclides Fernandes,Fernanda Maria Serafim Casimiro,Gustavo Ferreira da Mata,Michelle Tiveron Passos,Patrícia Siqueira Varela,Gianna Mastroianni-Kirsztajn,João Bosco Pesquero +7 more
TL;DR: Some drugs already in the market with potential CatL inhibiting capacity that could be used to treat COVID-19 patients are described and the possible role of host genetics in the etiology and spreading of the disease is discussed.
Journal ArticleDOI
COVID-19: A review of the proposed pharmacological treatments.
TL;DR: The drug candidates that have been suggested to treat COVID-19 will be discussed and the mechanisms of action and further pharmacological properties will be explored, with a particular focus on the evidence-based safety and efficacy of each agent.
References
More filters
Journal ArticleDOI
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.
Daniel Wrapp,Nianshuang Wang,Kizzmekia S. Corbett,Jory A. Goldsmith,Ching-Lin Hsieh,Olubukola M. Abiona,Barney S. Graham,Jason S. McLellan +7 more
TL;DR: The authors show that this protein binds at least 10 times more tightly than the corresponding spike protein of severe acute respiratory syndrome (SARS)–CoV to their common host cell receptor, and test several published SARS-CoV RBD-specific monoclonal antibodies found that they do not have appreciable binding to 2019-nCoV S, suggesting that antibody cross-reactivity may be limited between the two RBDs.
Journal ArticleDOI
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Manli Wang,Ruiyuan Cao,Leike Zhang,Xing-Lou Yang,Jia Liu,Mingyue Xu,Zhengli Shi,Zhihong Hu,Wu Zhong,Gengfu Xiao +9 more
TL;DR: This study evaluated the antiviral efficiency of five FAD-approved drugs including ribavirin, penciclovir, nitazoxanide, nafamostat, chloroquine and two well-known broad-spectrum antiviral drugs remdesivir and favipiravir against a clinical isolate of 2019-nCoV in vitro.
Journal ArticleDOI
Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis
TL;DR: ACE2 is abundantly present in humans in the epithelia of the lung and small intestine, which might provide possible routes of entry for the SARS‐CoV.
Journal ArticleDOI
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
Andrew Rhodes,Laura Evans,Waleed Alhazzani,Mitchell M. Levy,Massimo Antonelli,Ricard Ferrer,Anand Kumar,Jonathan E. Sevransky,Charles L. Sprung,Mark E. Nunnally,Bram Rochwerg,Gordon D. Rubenfeld,Derek C. Angus,Djillali Annane,Richard Beale,Geoffrey J. Bellinghan,Gordon R. Bernard,Jean Daniel Chiche,Craig M. Coopersmith,Daniel De Backer,Craig French,Seitaro Fujishima,Herwig Gerlach,Jorge Hidalgo,Steven M. Hollenberg,Alan E. Jones,Dilip R. Karnad,Ruth M. Kleinpell,Younsuck Koh,Thiago Lisboa,Flávia Ribeiro Machado,John J. Marini,John C. Marshall,John E. Mazuski,Lauralyn McIntyre,Anthony S. McLean,Sangeeta Mehta,Rui Moreno,John Myburgh,Paolo Navalesi,Osamu Nishida,Tiffany M. Osborn,Anders Perner,Colleen M. Plunkett,Marco Ranieri,Christa A. Schorr,Maureen A. Seckel,Christopher W. Seymour,Lisa Shieh,Khalid A. Shukri,Steven Q. Simpson,Mervyn Singer,B. Taylor Thompson,Sean R. Townsend,Thomas Van der Poll,Jean Louis Vincent,W. Joost Wiersinga,Janice L. Zimmerman,R. Phillip Dellinger +58 more
TL;DR: Although a significant number of aspects of care have relatively weak support, evidence-based recommendations regarding the acute management of sepsis and septic shock are the foundation of improved outcomes for these critically ill patients with high mortality.
Journal ArticleDOI
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
Bin Cao,Yeming Wang,Danning Wen,Wen Liu,Jingli Wang,Guohui Fan,Lianguo Ruan,Bin Song,Yanping Cai,Ming Wei,Xingwang Li,Jia'an Xia,Nanshan Chen,Jie Xiang,Ting Yu,Tao Bai,Xuelei Xie,Li Zhang,Caihong Li,Ye Yuan,Hua Chen,Huadong Li,Hanping Huang,Shengjing Tu,Fengyun Gong,Ying Liu,Yuan Wei,Chongya Dong,Fei Zhou,Xiaoying Gu,Jiuyang Xu,Zhibo Liu,Yi Zhang,Li Hui,Lianhan Shang,Ke Wang,Kunxia Li,Xia Zhou,Xuan Dong,Zhaohui Qu,Sixia Lu,Xujuan Hu,Shunan Ruan,Shanshan Luo,Jing Wu,Lu Peng,Fang Cheng,Lihong Pan,Jun Zou,Chunmin Jia,Juan Wang,Xia Liu,Shuzhen Wang,Xudong Wu,Qin Ge,Jing He,Haiyan Zhan,Fang Qiu,Li Guo,Chaolin Huang,Thomas Jaki,Frederick G. Hayden,Peter Horby,Dingyu Zhang,Chen Wang +64 more
TL;DR: In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care, and future trials in patients withsevere illness may help to confirm or exclude the possibility of a treatment benefit.
Related Papers (5)
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
Bin Cao,Yeming Wang,Danning Wen,Wen Liu,Jingli Wang,Guohui Fan,Lianguo Ruan,Bin Song,Yanping Cai,Ming Wei,Xingwang Li,Jia'an Xia,Nanshan Chen,Jie Xiang,Ting Yu,Tao Bai,Xuelei Xie,Li Zhang,Caihong Li,Ye Yuan,Hua Chen,Huadong Li,Hanping Huang,Shengjing Tu,Fengyun Gong,Ying Liu,Yuan Wei,Chongya Dong,Fei Zhou,Xiaoying Gu,Jiuyang Xu,Zhibo Liu,Yi Zhang,Li Hui,Lianhan Shang,Ke Wang,Kunxia Li,Xia Zhou,Xuan Dong,Zhaohui Qu,Sixia Lu,Xujuan Hu,Shunan Ruan,Shanshan Luo,Jing Wu,Lu Peng,Fang Cheng,Lihong Pan,Jun Zou,Chunmin Jia,Juan Wang,Xia Liu,Shuzhen Wang,Xudong Wu,Qin Ge,Jing He,Haiyan Zhan,Fang Qiu,Li Guo,Chaolin Huang,Thomas Jaki,Frederick G. Hayden,Peter Horby,Dingyu Zhang,Chen Wang +64 more
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou,Xing-Lou Yang,Xian Guang Wang,Ben Hu,Lei Zhang,Wei Zhang,Hao Rui Si,Yan Zhu,Bei Li,Chao Lin Huang,Hui-Dong Chen,Jing Chen,Yun Luo,Hua Guo,Ren Di Jiang,Meiqin Liu,Ying Chen,Xu Rui Shen,Xi Wang,Xiao Shuang Zheng,Kai Zhao,Quanjiao Chen,Fei Deng,Lin Lin Liu,Bing Yan,Fa Xian Zhan,Yan-Yi Wang,Gengfu Xiao,Zhengli Shi +28 more